Obsessive-Compulsive Disorder study: Psychotherapy
Official title Towards Remission and Full Recovery From Obsessive-compulsive Disorder
ClinicalTrials.gov ID: NCT06318806
What this study is testing
- What it's testing
- The study wants to see if inference‑based cognitive behavioral therapy works better than additional exposure and response prevention for people who didn’t reach remission. It also aims to find clues that predict who won’t respond to ERP.
- Who it's for
- Adults with obsessive‑compulsive disorder who have already tried exposure and response prevention but still have significant symptoms.
- What's involved
- Participants will be randomly assigned to receive either inference‑based CBT or more ERP sessions, with regular therapy appointments and symptom assessments.
- Time commitment
- The trial runs for several weeks, requiring participants to attend therapy visits and complete study assessments during that time.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- a primary diagnosis of OCD according to DSM-5 criteria.
- a score ≥ 18 on the Y-BOCS
- age ≥ 18.
- no change in medication during the 8 weeks before treatment for antidepressants (4 weeks for anxiolytics).
- willingness to keep medication stable while participating in the study.
You likely can't join if
- evidence of a high level of suicidal ideation, suicidal intent or previous suicide attempts.
- past or present psychotic or bipolar disorder.
- neurocognitive disorder, pervasive developmental disorder or intellectual disability of a severity judged to significantly interfere with treatment...
- substance abuse disorder of a severity judged to significantly interfere with treatment and/or requiring treatment first.
See the full eligibility criteria
- a primary diagnosis of OCD according to DSM-5 criteria.
- a score ≥ 18 on the Y-BOCS
- age ≥ 18.
- no change in medication during the 8 weeks before treatment for antidepressants (4 weeks for anxiolytics).
- willingness to keep medication stable while participating in the study.
- not undergoing a concurrent psychological treatment.
- access to a computer or phone with internet access.
- evidence of a high level of suicidal ideation, suicidal intent or previous suicide attempts.
- past or present psychotic or bipolar disorder.
- neurocognitive disorder, pervasive developmental disorder or intellectual disability of a severity judged to significantly interfere with treatment and/or requiring treatment first.
- substance abuse disorder of a severity judged to significantly interfere with treatment and/or requiring treatment first.
The study team makes the final eligibility decision.
Where it is enrolling
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.